Bepotastine

Dermatologic and Ophthalmic Drugs Advisory Committee Unanimously Recommends Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

...hing associated with allergic conjunctivitis. bepotastine was approved in Japan for use as a systemic drug i...sian countries, to develop, manufacture and market bepotastine for ophthalmic use. In 2006, ISTA licensed the ex...an rights from Senju to an eye drop formulation of bepotastine for the treatment of allergic conjunctivitis. ...

ISTA Pharmaceuticals Announces FDA Advisory Committee to Review Bepreve(TM) for the Treatment of Ocular Itching Associated with Allergic Conjunctivitis

...ons in the primary endpoints of ocular itching. As bepotastine is a new chemical entity in the U.S., ISTA expecte...hing associated with allergic conjunctivitis. bepotastine was approved in Japan for use as a systemic drug i...sian countries, to develop, manufacture and market bepotastine for ophthalmic use. In 2006, ISTA licensed the ex...

ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments

...- ISTA acquires exclusive North American rights to bepotastine for nasal allergy - ...rican rights to ophthalmic allergy applications of bepotastine and has been developing an ocular formulation of bepotastine to treat the symptoms of ocular itching that accom...

Bepotastine in Medical Technology

ISTA Pharmaceuticals Highlights Bepreve(TM) Clinical Data at the Association for Research in Vision and Ophthalmology (ARVO) 2009 Annual Meeting

... In another poster presentation titled "The Safety of the Anti-Histamine bepotastine Besilate Ophthalmic Solution in a Healthy Pediatric Population from Ten to .... The results were presented in the following poster presentations: bepotastine Besilate Ophthalmic Solution 1.0% Rapidly Reduces Conjunctival Hyperemia in...

ISTA Pharmaceuticals' New Drug Application for Bepreve(TM) Accepted for Review by U.S. Food and Drug Administration

...igns and symptoms of allergic conjunctivitis. bepotastine was approved in Japan for use as a systemic drug i...sian countries, to develop, manufacture and market bepotastine for ophthalmic use. In 2006, ISTA licensed the ex...an rights from Senju to an eye drop formulation of bepotastine for the treatment of allergic conjunctivitis. ...

ISTA Pharmaceuticals Announces New Phase III Clinical Findings to Support Bepreve NDA Filing

...tive treatment against the signs and symptoms of allergic conjunctivitis. bepotastine was approved in Japan for use as a systemic drug in the treatment of allerg...rom Senju the exclusive North American rights to an eye drop formulation of bepotastine for the treatment of allergic conjunctivitis. About ISTA Pharmaceuticals ...

Dr. Calvin Grant Presents Results from Xibrom(TM) Combination Therapy with Lucentis(R) at the 2008 Annual Meeting of the Association for Research in Vision and Ophthalmology (ARVO)

... uncertainties related to ISTA's research and development programs (including without limitation the difficulty of predicting the timing or outcome of bepotastine product development efforts); the timing, scope, and outcome of FDA or other regulatory agency approval or actions; uncertainties and risks regarding ...

ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)

... uncertainties related to ISTA's research and development programs (including without limitation the difficulty of predicting the timing or outcome of bepotastine product development efforts); the timing, scope, and outcome of FDA or other regulatory agency approval or actions; uncertainties and risks regarding ...

ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine

...nalysis of its U.S. Phase II/III clinical study of bepotastine for the treatment of allergic conjunctivitis. The ...s of the study were the assessment of efficacy for bepotastine in treating ocular itching and redness. The prelim...on of the second primary endpoint, ocular redness, bepotastine showed a trend toward clinical significance, but d...

Bepotastine in Biological Technology

ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)

...e signs and symptoms of allergic conjunctivitis. bepotastine was approved in Japan for use as a systemic drug i...sian countries, to develop, manufacture and market bepotastine for ophthalmic use. In 2006, ISTA licensed the exc...an rights from Senju to an eye drop formulation of bepotastine for the treatment of allergic conjunctivitis. Ab...